Compare Freeport-McMoRan Inc (FCX) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? Freeport-McMoRan Inc trades at $68.72 (market cap $104.00B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Freeport-McMoRan Inc is far larger — about 12.3× Hinge Health Inc. Class A Common Stock's market cap, and Freeport-McMoRan Inc pays a 0.83% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 70 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FCX | HNGE | |
|---|---|---|
Market Cap | $104.00B | $8.48B |
Volume | 7,316,762 | 879,799 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $105.14 |
52-Week Low | $38.65 | $31.17 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $110.28B | $8.10B |
Dividend Yield | 0.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $72.42, down 1.19% today, with a bullish technical signal from moving averages and a consensus analyst price target of $73.50. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue reached $25.92B in 2025, and net income margin improved to 11.38%. Strong cash flow from operations of $5.61B supports dividend payments and growth projects amid rising copper demand driven by AI and data centers.
FCX presents a positive outlook with robust fundamentals and favorable copper market dynamics, but faces risks from cost pressures and regulatory scrutiny. Earnings growth and expansion initiatives are key catalysts, while investor sentiment remains bullish based on analyst ratings.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
